Aptus Pharma Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Aptus Pharma Ltd is ₹ 430.4 as of 11 May 15:30 . The P/E Ratio of Aptus Pharma Ltd is 0 as of March 2023 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 . The Market Cap of Aptus Pharma Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Aptus Pharma Ltd is 0 % as of March 2023 .The Dividend Payout of Sai Parenterals Ltd is 0 % as of March 2023.

About Aptus Pharma Ltd

Aptus Pharma Limited was originally incorporated as 'Aptus Pharma Private Limited', as a private limited company with the Registrar of Companies, Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010.
Subsequently, Company was converted into a public limited retaining the name as 'Aptus Pharma Limited' and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations.
While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model with 7 units. under various arrangements.
It provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products.

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Aptus Pharma Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Aptus Pharma Ltd or Sai Parenterals Ltd?

Market cap of Aptus Pharma Ltd is 295 Cr while Market cap of Sai Parenterals Ltd is 2,152 Cr

What are the key factors driving the stock performance of Aptus Pharma Ltd and Sai Parenterals Ltd?

The stock performance of Aptus Pharma Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aptus Pharma Ltd and Sai Parenterals Ltd?

As of May 12, 2026, the Aptus Pharma Ltd stock price is INR ₹430.4. On the other hand, Sai Parenterals Ltd stock price is INR ₹487.2.

How do dividend payouts of Aptus Pharma Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Aptus Pharma Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.